Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by SHEKHAR GHAMANDE and MANJUSHA GAGLANI.
SHEKHAR GHAMANDE
Connection Strength
2.460
MANJUSHA GAGLANI
  1. Vaccine Effectiveness Against Acute Respiratory Illness Hospitalizations for Influenza-Associated Pneumonia During the 2015-2016 to 2017-2018 Seasons: US Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). Clin Infect Dis. 2022 04 28; 74(8):1329-1337.
    View in: PubMed
    Score: 0.861
  2. Vaccine Effectiveness Against Influenza A-Associated Hospitalization, Organ Failure, and Death: United States, 2022-2023. Clin Infect Dis. 2024 Apr 10; 78(4):1056-1064.
    View in: PubMed
    Score: 0.062
  3. Severity of Respiratory Syncytial Virus vs COVID-19 and Influenza Among Hospitalized US Adults. JAMA Netw Open. 2024 Apr 01; 7(4):e244954.
    View in: PubMed
    Score: 0.061
  4. Disease Severity of Respiratory Syncytial Virus Compared with COVID-19 and Influenza Among Hospitalized Adults Aged =60 Years - IVY Network, 20 U.S. States, February 2022-May 2023. MMWR Morb Mortal Wkly Rep. 2023 Oct 06; 72(40):1083-1088.
    View in: PubMed
    Score: 0.059
  5. Changing Severity and Epidemiology of Adults Hospitalized With Coronavirus Disease 2019 (COVID-19) in the United States After Introduction of COVID-19 Vaccines, March 2021-August 2022. Clin Infect Dis. 2023 08 22; 77(4):547-557.
    View in: PubMed
    Score: 0.059
  6. Total and Subgenomic RNA Viral Load in Patients Infected With SARS-CoV-2 Alpha, Delta, and Omicron Variants. J Infect Dis. 2023 08 11; 228(3):235-244.
    View in: PubMed
    Score: 0.059
  7. Prevalence and Clinical Outcomes of Respiratory Syncytial Virus vs Influenza in Adults Hospitalized With Acute Respiratory Illness From a Prospective Multicenter Study. Clin Infect Dis. 2023 06 08; 76(11):1980-1988.
    View in: PubMed
    Score: 0.058
  8. Comparison of mRNA vaccine effectiveness against COVID-19-associated hospitalization by vaccination source: Immunization information systems, electronic medical records, and self-report-IVY Network, February 1-August 31, 2022. Vaccine. 2023 06 29; 41(29):4249-4256.
    View in: PubMed
    Score: 0.058
  9. Effectiveness of Monovalent mRNA COVID-19 Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death Among Immunocompetent Adults During the Omicron Variant Period - IVY Network, 19 U.S. States, February 1, 2022-January 31, 2023. MMWR Morb Mortal Wkly Rep. 2023 Apr 28; 72(17):463-468.
    View in: PubMed
    Score: 0.058
  10. Protection of Messenger RNA Vaccines Against Hospitalized Coronavirus Disease 2019 in Adults Over the First Year Following Authorization in the United States. Clin Infect Dis. 2023 02 08; 76(3):e460-e468.
    View in: PubMed
    Score: 0.057
  11. Absolute and Relative Vaccine Effectiveness of Primary and Booster Series of COVID-19 Vaccines (mRNA and Adenovirus Vector) Against COVID-19 Hospitalizations in the United States, December 2021-April 2022. Open Forum Infect Dis. 2023 Jan; 10(1):ofac698.
    View in: PubMed
    Score: 0.056
  12. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged =65 Years - IVY Network, 18 States, September 8-November 30, 2022. MMWR Morb Mortal Wkly Rep. 2022 Dec 30; 71(5152):1625-1630.
    View in: PubMed
    Score: 0.056
  13. Comparison of test-negative and syndrome-negative controls in SARS-CoV-2 vaccine effectiveness evaluations for preventing COVID-19 hospitalizations in the United States. Vaccine. 2022 11 15; 40(48):6979-6986.
    View in: PubMed
    Score: 0.056
  14. Effectiveness of Monovalent mRNA Vaccines Against COVID-19-Associated Hospitalization Among Immunocompetent Adults During BA.1/BA.2 and BA.4/BA.5 Predominant Periods of SARS-CoV-2 Omicron Variant in the United States - IVY Network, 18 States, December 26, 2021-August 31, 2022. MMWR Morb Mortal Wkly Rep. 2022 Oct 21; 71(42):1327-1334.
    View in: PubMed
    Score: 0.056
  15. Effectiveness of the Ad26.COV2.S (Johnson & Johnson) Coronavirus Disease 2019 (COVID-19) Vaccine for Preventing COVID-19 Hospitalizations and Progression to High Disease Severity in the United States. Clin Infect Dis. 2022 Oct 03; 75(Supplement_2):S159-S166.
    View in: PubMed
    Score: 0.055
  16. mRNA Vaccine Effectiveness Against Coronavirus Disease 2019 Hospitalization Among Solid Organ Transplant Recipients. J Infect Dis. 2022 09 13; 226(5):797-807.
    View in: PubMed
    Score: 0.055
  17. Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States. medRxiv. 2022 Jun 14.
    View in: PubMed
    Score: 0.054
  18. Effectiveness of mRNA Vaccines Against COVID-19 Hospitalization by Age and Chronic Medical Conditions Burden Among Immunocompetent US Adults, March-August 2021. J Infect Dis. 2022 05 16; 225(10):1694-1700.
    View in: PubMed
    Score: 0.054
  19. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Clin Infect Dis. 2022 05 03; 74(9):1515-1524.
    View in: PubMed
    Score: 0.054
  20. Effectiveness of mRNA Vaccination in Preventing COVID-19-Associated Invasive Mechanical Ventilation and Death - United States, March 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 25; 71(12):459-465.
    View in: PubMed
    Score: 0.053
  21. Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the United States: prospective observational study. BMJ. 2022 03 09; 376:e069761.
    View in: PubMed
    Score: 0.053
  22. Clinical Severity and mRNA Vaccine Effectiveness for Omicron, Delta, and Alpha SARS-CoV-2 Variants in the United States: A Prospective Observational Study. medRxiv. 2022 Feb 07.
    View in: PubMed
    Score: 0.053
  23. Effectiveness of a Third Dose of Pfizer-BioNTech and Moderna Vaccines in Preventing COVID-19 Hospitalization Among Immunocompetent and Immunocompromised Adults - United States, August-December 2021. MMWR Morb Mortal Wkly Rep. 2022 Jan 28; 71(4):118-124.
    View in: PubMed
    Score: 0.053
  24. Coronavirus disease 2019 (COVID-19) Versus Influenza in Hospitalized Adult Patients in the United States: Differences in Demographic and Severity Indicators. Clin Infect Dis. 2021 12 16; 73(12):2240-2247.
    View in: PubMed
    Score: 0.052
  25. Association Between mRNA Vaccination and COVID-19 Hospitalization and Disease Severity. JAMA. 2021 11 23; 326(20):2043-2054.
    View in: PubMed
    Score: 0.052
  26. Comparative Effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) Vaccines in Preventing COVID-19 Hospitalizations Among Adults Without Immunocompromising Conditions - United States, March-August 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 24; 70(38):1337-1343.
    View in: PubMed
    Score: 0.052
  27. Sustained Effectiveness of Pfizer-BioNTech and Moderna Vaccines Against COVID-19 Associated Hospitalizations Among Adults - United States, March-July 2021. MMWR Morb Mortal Wkly Rep. 2021 Aug 27; 70(34):1156-1162.
    View in: PubMed
    Score: 0.051
  28. Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States. medRxiv. 2021 Jul 08.
    View in: PubMed
    Score: 0.051
  29. Vaccine Effectiveness Against Influenza-Associated Hospitalizations Among Adults, 2018-2019, US Hospitalized Adult Influenza Vaccine Effectiveness Network. J Infect Dis. 2021 07 02; 224(1):151-163.
    View in: PubMed
    Score: 0.051
  30. Low Influenza Vaccine Effectiveness Against A(H3N2)-Associated Hospitalizations in 2016-2017 and 2017-2018 of the Hospitalized Adult Influenza Vaccine Effectiveness Network (HAIVEN). J Infect Dis. 2021 06 15; 223(12):2062-2071.
    View in: PubMed
    Score: 0.051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.